2023-06-012024-05-312024-05-31false07648707SES MEDICAL WRITING LTD2025-01-2174909falseiso4217:GBPxbrli:pure076487072023-06-01076487072024-05-31076487072023-06-012024-05-31076487072022-06-01076487072023-05-31076487072022-06-012023-05-3107648707bus:SmallEntities2023-06-012024-05-3107648707bus:AuditExempt-NoAccountantsReport2023-06-012024-05-3107648707bus:FullAccounts2023-06-012024-05-3107648707bus:PrivateLimitedCompanyLtd2023-06-012024-05-3107648707core:WithinOneYear2024-05-3107648707core:AfterOneYear2024-05-3107648707core:WithinOneYear2023-05-3107648707core:AfterOneYear2023-05-3107648707core:ShareCapital2024-05-3107648707core:SharePremium2024-05-3107648707core:RevaluationReserve2024-05-3107648707core:OtherReservesSubtotal2024-05-3107648707core:RetainedEarningsAccumulatedLosses2024-05-3107648707core:ShareCapital2023-05-3107648707core:SharePremium2023-05-3107648707core:RevaluationReserve2023-05-3107648707core:OtherReservesSubtotal2023-05-3107648707core:RetainedEarningsAccumulatedLosses2023-05-3107648707core:LandBuildings2024-05-3107648707core:PlantMachinery2024-05-3107648707core:Vehicles2024-05-3107648707core:FurnitureFittings2024-05-3107648707core:OfficeEquipment2024-05-3107648707core:NetGoodwill2024-05-3107648707core:IntangibleAssetsOtherThanGoodwill2024-05-3107648707core:ListedExchangeTraded2024-05-3107648707core:UnlistedNon-exchangeTraded2024-05-3107648707core:LandBuildings2023-05-3107648707core:PlantMachinery2023-05-3107648707core:Vehicles2023-05-3107648707core:FurnitureFittings2023-05-3107648707core:OfficeEquipment2023-05-3107648707core:NetGoodwill2023-05-3107648707core:IntangibleAssetsOtherThanGoodwill2023-05-3107648707core:ListedExchangeTraded2023-05-3107648707core:UnlistedNon-exchangeTraded2023-05-3107648707core:LandBuildings2023-06-012024-05-3107648707core:PlantMachinery2023-06-012024-05-3107648707core:Vehicles2023-06-012024-05-3107648707core:FurnitureFittings2023-06-012024-05-3107648707core:OfficeEquipment2023-06-012024-05-3107648707core:NetGoodwill2023-06-012024-05-3107648707core:IntangibleAssetsOtherThanGoodwill2023-06-012024-05-3107648707core:ListedExchangeTraded2023-06-012024-05-3107648707core:UnlistedNon-exchangeTraded2023-06-012024-05-3107648707core:MoreThanFiveYears2023-06-012024-05-3107648707core:Non-currentFinancialInstruments2024-05-3107648707core:Non-currentFinancialInstruments2023-05-3107648707dpl:CostSales2023-06-012024-05-3107648707dpl:DistributionCosts2023-06-012024-05-3107648707core:LandBuildings2023-06-012024-05-3107648707core:PlantMachinery2023-06-012024-05-3107648707core:Vehicles2023-06-012024-05-3107648707core:FurnitureFittings2023-06-012024-05-3107648707core:OfficeEquipment2023-06-012024-05-3107648707dpl:AdministrativeExpenses2023-06-012024-05-3107648707core:NetGoodwill2023-06-012024-05-3107648707core:IntangibleAssetsOtherThanGoodwill2023-06-012024-05-3107648707dpl:GroupUndertakings2023-06-012024-05-3107648707dpl:ParticipatingInterests2023-06-012024-05-3107648707dpl:GroupUndertakingscore:ListedExchangeTraded2023-06-012024-05-3107648707core:ListedExchangeTraded2023-06-012024-05-3107648707dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-06-012024-05-3107648707core:UnlistedNon-exchangeTraded2023-06-012024-05-3107648707dpl:CostSales2022-06-012023-05-3107648707dpl:DistributionCosts2022-06-012023-05-3107648707core:LandBuildings2022-06-012023-05-3107648707core:PlantMachinery2022-06-012023-05-3107648707core:Vehicles2022-06-012023-05-3107648707core:FurnitureFittings2022-06-012023-05-3107648707core:OfficeEquipment2022-06-012023-05-3107648707dpl:AdministrativeExpenses2022-06-012023-05-3107648707core:NetGoodwill2022-06-012023-05-3107648707core:IntangibleAssetsOtherThanGoodwill2022-06-012023-05-3107648707dpl:GroupUndertakings2022-06-012023-05-3107648707dpl:ParticipatingInterests2022-06-012023-05-3107648707dpl:GroupUndertakingscore:ListedExchangeTraded2022-06-012023-05-3107648707core:ListedExchangeTraded2022-06-012023-05-3107648707dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-06-012023-05-3107648707core:UnlistedNon-exchangeTraded2022-06-012023-05-3107648707core:NetGoodwill2024-05-3107648707core:IntangibleAssetsOtherThanGoodwill2024-05-3107648707core:LandBuildings2024-05-3107648707core:PlantMachinery2024-05-3107648707core:Vehicles2024-05-3107648707core:FurnitureFittings2024-05-3107648707core:OfficeEquipment2024-05-3107648707core:AfterOneYear2024-05-3107648707core:WithinOneYear2024-05-3107648707core:ListedExchangeTraded2024-05-3107648707core:UnlistedNon-exchangeTraded2024-05-3107648707core:ShareCapital2024-05-3107648707core:SharePremium2024-05-3107648707core:RevaluationReserve2024-05-3107648707core:OtherReservesSubtotal2024-05-3107648707core:RetainedEarningsAccumulatedLosses2024-05-3107648707core:NetGoodwill2023-05-3107648707core:IntangibleAssetsOtherThanGoodwill2023-05-3107648707core:LandBuildings2023-05-3107648707core:PlantMachinery2023-05-3107648707core:Vehicles2023-05-3107648707core:FurnitureFittings2023-05-3107648707core:OfficeEquipment2023-05-3107648707core:AfterOneYear2023-05-3107648707core:WithinOneYear2023-05-3107648707core:ListedExchangeTraded2023-05-3107648707core:UnlistedNon-exchangeTraded2023-05-3107648707core:ShareCapital2023-05-3107648707core:SharePremium2023-05-3107648707core:RevaluationReserve2023-05-3107648707core:OtherReservesSubtotal2023-05-3107648707core:RetainedEarningsAccumulatedLosses2023-05-3107648707core:NetGoodwill2022-06-0107648707core:IntangibleAssetsOtherThanGoodwill2022-06-0107648707core:LandBuildings2022-06-0107648707core:PlantMachinery2022-06-0107648707core:Vehicles2022-06-0107648707core:FurnitureFittings2022-06-0107648707core:OfficeEquipment2022-06-0107648707core:AfterOneYear2022-06-0107648707core:WithinOneYear2022-06-0107648707core:ListedExchangeTraded2022-06-0107648707core:UnlistedNon-exchangeTraded2022-06-0107648707core:ShareCapital2022-06-0107648707core:SharePremium2022-06-0107648707core:RevaluationReserve2022-06-0107648707core:OtherReservesSubtotal2022-06-0107648707core:RetainedEarningsAccumulatedLosses2022-06-0107648707core:AfterOneYear2023-06-012024-05-3107648707core:WithinOneYear2023-06-012024-05-3107648707core:Non-currentFinancialInstrumentscore:CostValuation2023-06-012024-05-3107648707core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-06-012024-05-3107648707core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-06-012024-05-3107648707core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-06-012024-05-3107648707core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-06-012024-05-3107648707core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-06-012024-05-3107648707core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-06-012024-05-3107648707core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-06-012024-05-3107648707core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-06-012024-05-3107648707core:Non-currentFinancialInstrumentscore:CostValuation2024-05-3107648707core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-05-3107648707core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-05-3107648707core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-05-3107648707core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-05-3107648707core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-05-3107648707core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-05-3107648707core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-05-3107648707core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-05-3107648707core:Non-currentFinancialInstrumentscore:CostValuation2023-05-3107648707core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-05-3107648707core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-05-3107648707core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-05-3107648707core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-05-3107648707core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-05-3107648707core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-05-3107648707core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-05-3107648707core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-05-3107648707bus:Director12023-06-012024-05-31

SES MEDICAL WRITING LTD

Registered Number
07648707
(England and Wales)

Unaudited Financial Statements for the Year ended
31 May 2024

SES MEDICAL WRITING LTD
Company Information
for the year from 1 June 2023 to 31 May 2024

Director

SMITH, Suzanne, Dr

Company Secretary

SMITH, Suzanne, Dr

Registered Address

3 Rose Crescent
Leicester Forest East
Leicester
LE3 3QX

Registered Number

07648707 (England and Wales)
SES MEDICAL WRITING LTD
Balance Sheet as at
31 May 2024

Notes

2024

2023

£

£

£

£

Fixed assets
Tangible assets369318
69318
Current assets
Debtors410,124613
Cash at bank and on hand143,60495,702
153,72896,315
Creditors amounts falling due within one year5(134,276)(83,807)
Net current assets (liabilities)19,45212,508
Total assets less current liabilities19,52112,826
Net assets19,52112,826
Capital and reserves
Called up share capital100100
Profit and loss account19,42112,726
Shareholders' funds19,52112,826
The financial statements were approved and authorised for issue by the Director on 21 January 2025, and are signed on its behalf by:
SMITH, Suzanne, Dr
Director
Registered Company No. 07648707
SES MEDICAL WRITING LTD
Notes to the Financial Statements
for the year ended 31 May 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the rendering of services.
Revenue from sale of goods
Revenue from the sale of goods is recognised when the company has transferred to the buyer the significant risks and rewards of ownership of the goods, usually when goods are delivered and legal title has passed. Providing the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the company and the costs incurred or to be incurred in respect of the transition can be measured reliably.
Revenue from rendering of services
Revenue from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.
Employee benefits
Short-term employee benefits are measured at the undiscounted amount expected to be paid in exchange for the employee's services to the company. Where employees have accrued short-term benefits which the entity has not paid by the balance sheet date, an accrual is recognised within creditors: amounts falling due within one year together with an associated expense in profit or loss. The liabilities are classified as current obligations in the statement of financial position because they are expected to be settled wholly within twelve months after the end of the period.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Tangible fixed assets and depreciation
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:
2.Average number of employees

20242023
Average number of employees during the year11
3.Tangible fixed assets

Office Equipment

Total

££
Cost or valuation
At 01 June 232,2882,288
At 31 May 242,2882,288
Depreciation and impairment
At 01 June 231,9701,970
Charge for year249249
At 31 May 242,2192,219
Net book value
At 31 May 246969
At 31 May 23318318
4.Debtors: amounts due within one year

2024

2023

££
Trade debtors / trade receivables10,122612
Other debtors21
Total10,124613
5.Creditors: amounts due within one year

2024

2023

££
Trade creditors / trade payables6,694-
Bank borrowings and overdrafts6,150-
Taxation and social security12,1847,939
Other creditors109,24875,868
Total134,27683,807
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.